HFB200901
HFB200901 is a galectin LGALS9 inhibitor and immunostimulant that can be used in studies related to pancreatic adenocarcinoma, pancreatic intraepithelial neoplasia, KRASG12C-mutant colon cancer, and prostate cancer. HFB200901 disrupts the LGALS9/TIM-3 axis, while blocking the internalization and vacuolization of recombinant LGALS9. HFB200901 reduces the proportion of regulatory T cells (Treg) and enhances dendritic cell activation, thereby inducing polyfunctional and memory CD8+ T cell responses. HFB200901 inhibits the progression of pancreatic neoplastic lesions and effectively improves the efficacy of PSMA-based vaccination.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All Galectin Isoforms
More
Biological Activity
Human
Anti-LGALS9 (HFB200901) (10 μg/mL; 1 h) potently inhibits rLGALS9-induced vacuolization in MDCK and DLD-1 KRASG12C mutant colon carcinoma cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Pdx1-Cre; LSL-KrasG12D (KC) (2-month-old, transgenic model of early pancreatic carcinogenesis)[2]
-
Dosage:20 µg; 10 mg
-
Administration:s.c.; once weekly; 8 weeks
-
Result:Reduced overall pancreatic LGALS9 expression (RFI: 2.06) compared to isotype control (RFI: 3.04).
Reduced LGALS9 expression in non-immune pancreatic cells (CD45−) (RFI: 2.06) compared to isotype control (RFI: 3.98).
Increased pancreatic-infiltrating CD4+ T cells to 20.1% compared to 12.33% for isotype control.
Reduced peripheral and pancreatic-infiltrating Treg levels.
Decreased total PanIN surface area; all untreated mice developed ADM and PanIN 1 with 5/6 having at least one PanIN Ib/II, while all treated mice had ADM or PanIN 1 with only 1/6 having one PanIN Ib/II.
Left peripheral CD4+ T cell levels unchanged (13.97% vs 13.99% for isotype).
Galectin-9/LGALS9
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Wiersma VR, et al. The epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic flux. Autophagy. 2015;11(8):1373-1388. [Content Brief]
[2]. Quilbe A, et al. A novel anti-galectin-9 immunotherapy limits the early progression of pancreatic neoplastic lesions in transgenic mice. Front Immunol. 2023;14:1267279. Published 2023 Nov 30. [Content Brief]
[4]. Lu B, et al. LGALS9 blockade augments vaccine-induced immune responses against prostate cancer. J Immunother Cancer. 2026;14(5):e014141. Published 2026 May 8. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
HFB200901 Related Classifications
HY-P992366 Related Classifications
Powered by Bioz